Frankfurt
27.06.25 | 15:29
6,500 Euro
-2,26 % -0,150
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.06. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.05. | Fortress Biotech, Inc.: Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics | 177 | GlobeNewswire (Europe) | MIAMI, May 30, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value... ► Artikel lesen | |
| 15.05. | Fortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 248 | GlobeNewswire (Europe) | Emrosi commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint... ► Artikel lesen | |
| 16.04. | Fortress Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln | |||||
| 31.03. | Fortress Biotech, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 31.03. | Fortress Biotech, Inc.: Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights | 84 | GlobeNewswire (Europe) | Emrosi approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary... ► Artikel lesen | |
| 25.03. | Fortress Biotech FY 2024 Earnings Preview | 2 | Seeking Alpha | ||
| 17.03. | Fortress Biotech kooperiert mit Partex für KI-gestützte Arzneimittelentwicklung | 7 | Investing.com Deutsch | ||
| 17.03. | Fortress Biotech, Inc.: Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform | 158 | GlobeNewswire (Europe) | FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company, today announced a strategic... ► Artikel lesen | |
| 10.03. | Fortress Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.01. | Fortress Biotech, Inc.: Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT | 202 | GlobeNewswire (Europe) | Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the... ► Artikel lesen | |
| 16.01. | Fortress Biotech, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.01. | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease | 214 | GlobeNewswire (Europe) | Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones... ► Artikel lesen | |
| 06.01. | Fortress Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.24 | Fortress Biotech, Inc.: Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | 249 | GlobeNewswire (Europe) | Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally... ► Artikel lesen | |
| 13.08.24 | Fortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights | 271 | GlobeNewswire (Europe) | PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to... ► Artikel lesen | |
| 25.07.24 | Fortress Biotech, Inc.: Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 | 369 | GlobeNewswire (Europe) | MIAMI, July 25, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress", or the "Company"), an innovative biopharmaceutical company focused on acquiring and advancing assets to... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 334,90 | -0,39 % | Kurs der Stryker-Aktie verharrt auf Vortags-Niveau (324,7763 €) | Am US-amerikanischen Aktienmarkt ist die Stryker-Aktie aktuell unauffällig. Der jüngste Kurs betrug 374,99 US-Dollar. Die Wertschätzung der Börsenteilnehmer für die Aktie von Stryker hat sich heute... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 444,00 | -0,22 % | Bayer, Regeneron get EU nod for Eylea's label extension | ||
| VIKING THERAPEUTICS | 22,700 | +0,13 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
| TEMPUS AI | 56,44 | -0,67 % | Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -0,67 % | Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock | ||
| NUREXONE BIOLOGIC | 0,450 | +2,27 % | Biotech-Pick: Warum sie diese Aktie unbedingt auf dem Zettel haben sollten! | ||
| GINKGO BIOWORKS | 7,750 | -3,73 % | Ginkgo Bioworks stock rises on Hugging Face collaboration for AI drug development | ||
| IOVANCE BIOTHERAPEUTICS | 1,470 | +1,52 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,076 | +7,79 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma | SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the... ► Artikel lesen | |
| BIOMEA FUSION | 1,865 | -6,28 % | Biomea Fusion stock price target cut to $4 from $18 at H.C. Wainwright | ||
| TERNS PHARMACEUTICALS | 3,380 | +3,05 % | Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions | Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment... ► Artikel lesen | |
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data |
FORTRESS BIOTECH INC PREF gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,26 % bei einem Aktienkurs von 6,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTRESS BIOTECH INC PREF finden Sie auf Wallstreet Online.